一种特异性识别人微管相关蛋白的单克隆抗体及其应用
By using monoclonal antibodies that specifically recognize human microtubule-associated proteins, the challenges of early diagnosis and prediction of Alzheimer's disease (AD) have been solved, providing a highly sensitive tau protein detection method suitable for early diagnosis and drug development in AD.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- BEIJING JIAOTONG UNIV
- Filing Date
- 2023-07-03
- Publication Date
- 2026-07-17
AI Technical Summary
Among the existing diagnostic methods for Alzheimer's disease (AD), there are few treatments that target the tau protein, and the detection of blood-related biomarkers is not yet widely used, making early diagnosis and prediction of AD difficult.
A monoclonal antibody that specifically recognizes human microtubule-associated protein is provided, produced by the hybridoma cell line ZD8F7, for the preparation of a human tau protein quantitative detection kit. This kit can detect tau protein levels in cerebrospinal fluid and blood samples, enabling early diagnosis and prediction.
It enables early diagnosis and prediction of Alzheimer's disease (AD), improves the sensitivity and specificity of detection, and is suitable for screening healthy elderly populations and AD drug development.
Smart Images
Figure CN116622645B_ABST